PCN245 Opposing Duration of Treatment Effect Assumptions USED in the Health Technology Assessment of a Treatment for Rituximab-Refractory Follicular Lymphoma

Saved in:
Bibliographic Details
Published inValue in health Vol. 23; p. S466
Main Authors Davé, K., Strunz-McKendry, T., Felizzi, F., Launonen, A., Krivasi, T.
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.12.2020
Online AccessGet full text

Cover

More Information
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2020.08.382